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Edwin M. Horwitz,1 Richard T. Maziarz,2 Partow Kebriaei3INTRODUCTION
Mesenchymal stromal cells (MSCs), designated
mesenchymal stem cells by some investigators [1],
are a heterogeneous population of spindle-shaped,
plastic-adherent cells isolated from bone marrow, adi-
pose tissue, and many other tissue sources [2,3]. These
intriguing cells have been widely studied for many
disorders in both hematopoietic cell transplantation
and regenerative medicine.
AlthoughMSC research continues along many ave-
nues, this article will focus on theMSCs in close relation
to hematopoietic cell transplantation (HSC). To assist
the nonexpert, we have divided the article into 3 sections
discussing (I) the current view of the MSC mechanisms
of action for most applications, (II) MSCs as adjunct
therapy to foster HSC engraftment and hematopoietic
reconstitution, and (III)MSCs for prophylaxis and ther-
apy of graft-versus-host disease (GVHD).SECTION I: A NEW VIEWOF MSCS
Mesenchymal stromal cells (MSCs) were originally
identified by Friedenstein et al. [4] as the stromal cells
of the marrow microenvironment that support hema-
topoiesis. Soon thereafter,MSCswere shown to differ-
entiate into bone and have an immense capacity for
growth in cell culture in vitro. Friedenstein et al. [5]
further showed that a subset of the cells had a high pro-
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broblast colony-forming cells (CFU-F). It was then
discovered that MSCs could differentiate in vitro into
fat and cartilage as well as bone. At that time, the only
widely recognized stem cells were theHSCs, and based
largely on that model, adult stem cells were generally
defined as cells that could undergo self-renewal and
differentiation into at least 2 lineages. As there was no
clear distinction between in vivo and in vitro differenti-
ation capacity, MSC seemed to fulfill those criteria.
Owen [6] then proposed the existence of stromal stem
cells, analogous to the HSCs, that could reconstitute
the hematopoietic microenvironment, and suggested
the CFU-F may represent such cells. Later, Caplan
[7] noted thatMSCs fulfilled the self-renewal andmul-
tilineage differentiation criteria and proposed that
these cells were actuallyMSCs, with the capacity to dif-
ferentiate into a wide variety of mesenchymal tissues.
According to this concept, these MSCs could serve as
a broadly applicable stem cell source for regenerative
medicine, repopulating injured tissues and clinically
ablated diseased tissues with healthy, terminally differ-
entiated, tissue-specific cells [8,9].The New Paradigm of the MSC Mechanism
of Action
It has now been 15 years since the first report of
MSC infusion into humans [10]. Several thousand
patients have received systemically infused MSCs for
various indications. Interestingly, in all of these stud-
ies, the documented engraftment of donor cells at
the presumed site of activity is low or even completely
absent. Even in preclinical models, the engraftment is
exceedingly low. Despite our preconceived notions,
the most appropriate conclusion seems to be that, after
systemic infusion, there is no definitive evidence of
a therapeutic effect being mediated by engraftment
and terminal differentiation of MSCs to the cells of
the resident tissue. In other words, there is no evidence
of MSCs acting as ‘‘building blocks’’ to rebuild tissue
after systemic infusion. Given their feeble and tran-
sient engraftment, nevertheless resulting in substantial
clinical benefit, what molecular and cellular mecha-
nism may account for the striking biologic activity of
MSCs? An emerging body of data suggests that solubleS21
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mechanism of action for most, if not all, of the systemic
effects [11].
MSCs secrete stromal-derived factor-1 [12], which
plays a vital role in HSC homing to the niche in the
marrowmicroenvironment [13]. In vitro, MSCs consti-
tutively secrete interleukin (IL)-6, IL-7, IL-8, IL-11,
IL-12, IL-14, IL-15, macrophage-colony-stimulating
factor, Flt-3 ligand, and stem cell factor. Upon IL-1a
stimulation, MSCs are induced to express further
IL-1a, leukemia inhibitory factor (LIF), granulocyte-
colony-stimulating factor (G-CSF), and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [14].
Finally, MSCs can secrete several chemokine ligands,
including CCL2, CCL4, CCL5, CCL20, CX3CL1,
and CXCL8 [15].
The search for soluble mediators generated by
MSCs is an active area of investigation and will prob-
ably reveal a new array of important secreted signaling
molecules. These observations, together with the find-
ing that local engraftment and differentiation, is an un-
common event, suggest a new general paradigm for
MSC therapeutic activity. Systemically infused MSCs
exert a therapeutic effect primarily through the release
of soluble mediators that act on local and distant target
tissues. Rather than serving as stem cells to repair
tissues, they serve as cellular factories secreting medi-
ators to stimulate the repair of tissues or modulate the
local microenvironment to foster requisite beneficial
effects.The Impact of the New Paradigm
There are 2 key implications to the idea that the
principal mechanism of biologic activity after systemic
infusion of MSCs, in virtually all applications, is the
secretion of soluble mediators. First, the tissue source
of the MSCs may be critically important in determining
biologic activity. Despite the uniform morphology and
cell-surface marker expression, gene expression studies
show that populations of MSCs are heterogeneous
[16,17]. Whereas MSCs are often considered to be the
same general population of cells regardless of the tissue
source, recent data suggest that MSC gene expression
reflects their tissue of origin, indicating that MSC
tissue heterogeneity is biologically relevant [18,19].
Thus, different tissue sources may generate MSC
products with different cytokine expression profiles.
Hence, different MSC tissue sources may be especially
suited for specific clinical applications. Second,
isolation and culture expansion conditions may
significantly affect gene expression, and therefore the
bioactivity, of the cells. Such conditions include the
seeding density, culture media, serum supplementation,
and extent of ex vivo expansion. Furthermore,
bioreactors, in contrast to conventional plastic culture
flasks, may affect gene expression. These observationssuggest that the cell processing protocols can be
modified to enhance or repress expression of specific
genes in order to optimize the cytokine profile for
a given clinical indication.
What are the implications for the use of MSCs as
adjunct therapy in HCT? The 2 principle applications
are to enhance HSC engraftment and as prophylaxis
and/or therapy for GVHD. The work investigating
the use of MSCs to foster HSCs, which will be dis-
cussed in the next section, initially focused on repairing
the cellular constituency of themicroenvironment after
radiochemotherapy conditioning. Use ofMSCs to fos-
ter engraftment may merit a reexamination based on
the idea thatMSCsmay releasemediators that facilitate
engraftment and hematopoietic reconstitution without
actually rebuilding the microenvironment. The use of
MSCs in GVHD, which is also discussed later in this
article, is currently 1 of the most widely studied appli-
cations of MSCs. These studies are consistent with the
secreted mediator proposal, and the approaches being
studies are likely to yield optimal results.SECTION II: MESENCHYMAL STEM CELLS
(MSCS) AND HEMATOPOIESIS
The biologic relationship of stromal adherent stem
cells/MSCs and hematopoiesis has been long recog-
nized [5,20]. A variety of in vitro analyses have
clearly demonstrated augmentation of hematopoietic
stem cell (HSC) expansion upon coculture with ex
vivo-expandedMSCs, with contributions from trophic
factors and secreted cytokines as well as from direct
cellular interaction in which stromal stem cells and
their specific progenitors may provide a scaffold for
HSC growth and expansion [1,14,21-23]. All lineages
including lymphocyte expansion have been observed,
with megakaryocyte expansion most heralded given
the relative scarcity of these cells within the bone
marrow environment [24].
What remains to be determined is whether hemato-
poiesis can truly be augmented in vivo by application of
MSC in the human transplant setting [25,26].
Significant effort has focused on exploiting the paracrine
effect of stromal adherent stem cells on the HSCs, with
particular attention to the various secreted growth
factors and matrix components that have agonistic
effects on promoting HSC growth and differentiation as
well as cellular expansion [1,14,21,22,24]. Additionally,
the immune suppressive potential of MSCs has also
been highlighted, not only for therapeutic interventions,
but also for providing immune protection to potential
targeted HSCs [27-32]. Recent demonstration that
adherent stromal stem cells can modulate inflammatory
cytokine-mediated tissue injury suggests that hematopoi-
esis augmentationbyMSCmaynotbe confined togrowth
promotion but also include injury protection processes
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a or interferon (INF)-g associated with the inflammatory
state have been known to hinder HSC growth and
expansion, as has been demonstrated within the Fanconi
anemia model of bone marrow failure [37,38]. This
potential novel mechanism of MSC impact on
hematopoiesis has not yet been scrutinized to any
significant degree and remains a subject of intense
investigation.
Despite the encouraging observations of augmented
hematopoiesis by MSCs in vitro with confirmation of
these principles withmultiple preclinical animal models
[39-43], there still remains a dearth of human studies
that clearly document successful clinical augmentation
of hematopoiesis by MSCs. Clinical application
of MSCs could target enhancement of primary
engraftment, or conversely, for application in patients
experiencing or at risk for graft failure, recently
shown in a retrospective analysis of the Center for
International Blood and Marrow Transplant Research
(CIBMTR) to be associated with over 90% mortality
[44]. The first studies of interest were first published
over 15 years ago, and subsequently, several small
studies have been completed that confirm safety of
MSC infusion and perhaps demonstrate some utility,
but as of yet, no phase III randomized trials have mate-
rialized. In patients undergoing peripheral blood stem
cell transplantation (PBSCT) for rescue after high-
dose myeloablative chemotherapy for breast cancer,
coinfusion of autologous, ex vivo expanded MSC was
found to be safe, and interestingly, demonstrated both
neutrophil engraftment at a median of 8 days and
platelet engraftment at 8.5 days [45]. MSC were also
used specifically to target enhanced engraftment in
a study reported by LeBlanc et al. [46]. Seven patients,
3 of whom had already experienced graft failure/graft
rejection, and 4 patients for whom hematopoietic
engraftmentwere targeted for enhancement,were trans-
planted with HSCs and haploidentical MSCs, and all 7
achieved 100% donor chimerism with a median time
to both neutrophil and platelet engraftment of 12
days. Subsequently, several other small studies in haploi-
dentical HSC transplantation and of cord blood trans-
plantation cotransplanted with MSC have suggested
engraftment benefit, although this has not been univer-
sally confirmed [47-49].
What is intriguing iswhetherornotMSCtransplan-
tation by itself can provide therapeutic benefit. Cer-
tainly, this approach is being highlighted in the field of
regeneration medicine using MSC both for immuno-
modulatory therapeutics as well as for assisting in tissue
repair [32]. In HSCT, there have been isolated reports
in which solitary MSC infusion may have provided
therapeutic benefit. Specifically, Fouillard et al. [50] re-
ported a single patient who underwent autologous stem
cell transplantation for acute myelogenous leukemia
(AML) who subsequently experienced partial graftfailure, requiring ongoing growth factor in transfusion
support.Evenafter an intervalofover2 years hadpassed,
infusion of haploidentical MSCs from her brother was
associated with reversal of the defect in hematopoiesis.
Short-termbutnot long-termevidenceofMSCengraft-
ment was identified. Additionally, 6 patients with poor
hematopoietic recovery after allogeneic transplantation
were infused with donor-expanded MSC only [51]. It
was a suggestive result that 2 of the 6 patients experi-
enced rapid recovery of donor hematopoiesis, although
the other 4 failed to demonstrate benefit. Observations
such as these have led to great interest in MSCs being
considered for use as primary therapy for hematopoietic
injury. There have been animal studies to suggest that
cotransplantation of MSC with limiting doses of
HSC after radiation injury can lead to enhanced survival
of the animals associated with more rapid platelet
and neutrophil recovery [52,53]. Given these conside-
rations, MSC therapy has emerged as a potential
therapeutic maneuver for treatment of acute radiation
syndrome, in the event of nuclear accidents or
potential nuclear terrorist events, with a plan to
stockpile for the Department of Defense large
quantities of cryopreserved MSC. If FDA approval for
MSC for treatment of acute radiation syndrome is
eventually obtained, a staggered plan for delivery of
20,000 cryopreserved doses for the United States
Emergency Preparedness Network has been put in
place (Osiris, Inc., Website, announcement, 1/3/08).
Significantwork remains tobeperformed toactually
confirm that MSCs should be utilized routinely to sup-
port hematopoiesis with enough efficiency to demon-
strate a therapeutic benefit. Many questions remain
regarding efficacious dose, optimized and targeted de-
livery, and relevant efficacy measurements. Recently,
there have been interesting observations that umbilical
cord HCT directly transplanted within the medullary
cavity has been associated with improved engraftment
[54-56]. Certainly, many of the regeneration medicine
efforts surrounding neurologic or cardiac repair have
focused on issues of direct implantation versus
systemic intravenous delivery. Trafficking of MSCs to
relevant target areas is clearly confounded by
pulmonary vascular bed retention, and whether
augmentation of efficacy within the HSCT arena can
be improved upon by direct implantation within the
marrow cavity needs to be studied. A single case report
provides tantalizing data on this subject [57]. A 3-year-
old child with Wiscott-Aldrich syndrome underwent
haploidenticalHSCTfromhismotherwithdirect intra-
osseous injectionof preexpanded, donorMSCsunilater-
ally into the iliac crest at 6 different sites. No clinical
benefit could be documented, although posttransplant
assessment atday60withbilateral bonemarrowbiopsies
revealed markedly improved donor cellularity on the
treated hemipelvis compared to the untreated side. Ad-
ditionally, further efforts on using adherent stromal
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products in limited supply such as for cord blood trans-
plantation needs to be assessed [58-62]. Similarly, it
remains to be determined if MSCs can effectively
support haploidentical HSC transplantation perhaps
by taking advantage not only of the support for
hematopoiesis but also for protection of the donor
graft from host T cell destruction, as has been
proposed [47].
Finally, the characterization of MSC has been
defined by consensus as a result of a recent effort by in-
vestigators supported by the International Society for
Cellular Therapy (ISCT) [61]. However, no one ques-
tions that multiple adherent stromal stem cell popula-
tions have been identified, isolated from multiple
tissue sources and captured potentially at multiple dif-
ferentiation states [62]. Biologic properties may vary
between these various MSC sources, but to date,
side-by-side comparative trials have not yet been per-
formed nor has it been determined whether or not au-
tologous or allogeneic MSCs will be preferentially
utilized. What has been demonstrated is that delivery
can be performed safely, but all also agree that delivery
to tissue target areas have not yet been optimized [63],
and that long-term effects such as a deleterious effect
on the graft-versus-leukemia response remain a con-
cern [64]. Obviously, this would not be an issue if
MSC are proven to ultimately be best used in the au-
tologous setting or as a solitary product for defective
hematopoiesis, but it does remain an important but
unanswered issue in the setting of allogeneic HSCT.
Ultimately, we anticipate that these will be the novel
studies that will emerge over the next few years, recog-
nizing that the cost of product will necessarily dictate
close attention to viable and valid endpoints of trial
design.SECTION III: MSCS AND GVHD
Mesenchymal stromal cells (MSCs) are a population
of phenotypically heterogeneous cells marked by an
absence of hematopoietic markers (CD342, CD452),
and expression of CD73, CD90, and CD105 surface
markers, that can differentiate in vitro into osteoblasts,
chondroblasts, and adipocytes [65-68]. Furthermore,
MSC do not express HLA class II histocompatibility
antigens, or accessory molecules, CD40, CD80, and
CD86, required for immune cell activation, and thus,
histocompatibility matching is not required for
therapeutic effect [69]. Subpopulations may contribute
directly, and via paracrine effects, to immunomodula-
tion [70-73] and tissue repair [74-76]. Finally, MSCs
can be readily expanded and purified ex vivo from
bone marrow mononuclear cells obtained from
animals and humans [77,78]. These unique properties
make MSC a rationale agent to investigate for thetreatment of graft-versus-host disease (GVHD), which
results in significant morbidity and mortality following
allogeneic hematopoietic cell transplantation (HCT).
Immunomodulation
MSCs possess intrinsic immunoregulatory activi-
ties that are still not fully characterized, but broadly
modulate innate and adaptive immune responses
[72,79]. Within the context of innate immunity,
MSC alter antigen-presenting cell (APC) develop-
ment, maturation, and function. Dendritic cells
(DCs) are potent APC for na€ıve T cells, and are critical
in donor T cell activation during acute GVHD [80].
MSC inhibit differentiation of monocytes to DC,
and furthermore, affect DC differentiation, activation,
and function [72]. MSCs also inhibit natural killer
(NK) cell proliferation and cytokine production, and
could potentially modulate DC function through their
effects on NK cells [81]. Therefore, MSCs should sup-
press alloreactivation of donor T cells against the host
in the setting of GVHD. However, this is with the ca-
veat that acute GVHD (aGVHD) typically results in
high levels of interferon (INF)-g that may increase
MHC class II expression on MSC [80,82], and could
paradoxically augment GVHD.
Within the context of adaptive immunity, MSC
inhibit alloreactive T cell responses via contact-
dependent mechanisms and soluble factors [72,83], and
some studies suggest a shift in T cell function toward
a more regulatory phenotype [84]. Importantly, the ef-
fects of MSC on T cells are independent from HLA
matching between MSC and lymphocytes [69]. Sundin
and colleagues [85] evaluated the immunogenicity of
HLA-mismatched MSC infused after HCT. Recipient
lymphocyte response to MSC and peripheral blood
lymphocytes from the MSC or third party donors was
measured before and afterMSC infusion.Transplant re-
cipients givenMSC showed an allo-response to the third
party and MSC donor, but no immune response to
infused MSCs, suggesting immune unresponsiveness
restricted to the MSCs, rather than tolerance to the
MSCdonor; this lack of immune response was sustained
after repeated MSC infusions [85].
Tissue Repair
The role of MSC in tissue repair is under extensive
study. Of relevance to GVHD, a number of animal
models of injury including cerebral ischemia [86],
total-body irradiation (TBI) [87,88], and myocardial
infarction [89] have demonstrated a chemotactic re-
sponse of MSC to the site of injury. Once at the site
of injury or inflammation, it has been proposed that
MSC stimulate tissue repair of the affected organs.
This likely occurs via the paracrine effects of MSC
[90], rather than through direct MSC-mediated tissue
repair [91].
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Thus far, the majority of data for MSC are derived
from tissue culture experiments and nonhuman animal
models. However, some compelling clinical results
have been noted in therapeutic trials for GVHD
(Table 1). MSC have been most extensively studied in
steroid-refractory GVHD. LeBlanc and colleagues
[92] reported the first case of successful treatment of se-
vere refractory aGVHD of the gut and liver in a pediat-
ric patient using ex vivo expanded haploidentical human
MSC. Prompt response was observed after the addition
of MSC to the existing immunosuppressive regimen,
but symptoms recurred after discontinuation of immu-
nosuppression. Symptoms were responsive to a repeat
dose ofMSC [92]. Eight patients with steroid refractory
GVHD were subsequently treated with complete re-
sponse (CR) noted in 6 patients, and DNA from the
MSC donor detected in the colon of 1 patient 1 month
after MSC infusion [31]. These positive results were
corroborated in a nonrandomized, multicenter trial re-
ported by the European Blood and Marrow Transplant
MSC consortium, using a shared expansion protocol for
the cells and common reagents [93]. Twenty-five pedi-
atric and 30 adult patients were treated with sibling
HLA-identical, haploidentical, or third-party mis-
matched, bone marrow-derived MSC for steroid-
refractoryGVHD. A singleMSC infusion, withmedian
dose 1.4  106 MSC/kg, was infused into 27 patients
and the remaining patients were treated with 2 or
more infusions. The initial response rate was 70% (30
CR, 9 partial response [PR]). The median time from
infusion of first MSC to response was 18 days, with
19 patients with sustained CR at 6 weeks following in-
fusion. Patients with a CR had a statistically significant
lower treatment-related mortality (TRM) at 1-year and
overall survival (OS) at 2 years following transplant
compared to nonresponders, 37% versus 72%, P 5
.002, and 53% versus 16%, P 5 .018, respectively
[97]. The infusions were well tolerated with no signifi-
cant adverse events noted. There was a trend for better
response in the pediatric patients, with a statistically
better survival. The majority of patients received
third-party donors, precluding an efficacy analysis for
MSCmatch grade. Similar positive findings were noted
in a large, pediatric phase II study of third-party, mis-
matched MSC (Prochymal) for steroid-refractory
aGVHD. Fifty-nine patients, with median age 8 years
received 8 biweekly infusions of 2  106 MSCs/kg for
4 weeks, followed by additional 4 infusions weekly as
‘‘maintenance’’ in patients with PR. The majority of
patients had severe gut and liver GVHD, and had pro-
gressed through a median of 3.2 lines of prior therapy
forGVHD. At day 28, the overall response rate, defined
as organ improvement of at least 1 stage without wors-
ening in any other, was 64%. These patients had a sig-
nificantly better survival at 100 days compared topatients who did not achieve response at day 28, 76%
versus 9% [94]. Similar findings have been noted in
the remaining, smaller patient series using MSCs for
GVHD, with transiently higher response rates noted
than compared with historic data, and no significant
adverse effects noted with MSC infusion (Table 1)
[95-98].
There are fewer investigations of MSC for de novo
aGVHD. Kebriaei and colleagues [99] reported the re-
sults of a phase II trial designed for patients with grades
II-IV, de novo aGVHD. Thirty-two adult patients re-
ceived 2 treatments of MSC (Prochymal) at a dose of
either 2 or 8  106 MSCs/kg in combination with
a conventional corticosteroid regimen. Patients con-
tinued to receive GVHD prophylaxis with tacrolimus,
cyclosporine, or mycophenolate mofetil. Thirty-one
patients were evaluable, with 94% initial response
noted (24 CR, 5 PR). Nineteen of 24 CR were main-
tained for at least 90 days. No infusional toxicities
or ectopic tissue formation were reported. The trial
was not designed to detect a difference between the 2
different MSC doses, but no obvious differences
were observed [99].
Preliminary results from 2 multicenter, random-
ized, Phase III clinical trials for de novo acute and
steroid-refractory aGVHD have been reported
(September 8, 2009 http://investor.osiris.com/release
detail.cfm?ReleaseID5408763). In both studies weekly
or biweekly MSC (Prochymal) were administered for
4 weeks with individual dosing at 2  106 MSCs/kg.
Neither the steroid-refractory nor the newly diag-
nosed GVHD trials reached the primary endpoint of
durable CR $28 days. However, select patients with
either steroid-refractory liver or gastrointestinal
GVHD were reported to have significantly improved
response rates (81% versus 68%, P5 .035). No signif-
icant difference was noted with respect to toxicity or
recurrent malignancy rates [100]. Experience with
MSCs for the treatment of chronic GVHD (cGVHD)
is more limited. Three pediatric patients were treated
with MSC for cGVHD, with 1 patient showing slight
improvement after infusion of 3 million MSCs/kg
administered at 7 months and again at 26 months fol-
lowing transplant [96]. One patient with extensive
cGVHD was treated with 0.6  106 haploidentical
MSCs/kg at 5months following transplant, with no re-
sponse [31]. Of note, both this patient, and 1 of the
cGVHDpatients in the previous study, died eventually
of EBV-PTLD related complications [31,96].
In conclusion, the clinical experience with MSC
for the treatment of GVHD is encouraging, but in-
complete. Significant questions remain regarding the
optimal culture conditions, biodistribution, and
persistence ofMSC, as well as potential long-term tox-
icities and risk for infection. Future clinical trials
should be designed to determine the optimal dose
Table 1.
Study Indication N Med Age (Range) GVHD MSC Regimen (M, 106 MSC) Results
Kebriaei et al., 2009 [33] De novo acute GVHD 32 52 (34-67) Grade II: 21
Grade III: 8
Grade IV: 3
2 or 8 M/kg at 1 and 3 days after GVHD + steroids;
mismatched MSC
94% initial response (77% CR, 16% PR), 61%sustained CR;
No difference b/w high/low MSC dose; No infusional toxicity
Ringden et al., 2006 [26] Steroid refractory,
acute GVHD
8 56 (8-61) Grade II: 2
Grade III: 5
Grade IV:1
1 M/kg (range: 0.7-9);
1 dose (range: 1-2); mismatched/sib/haplo MSC
6/8 CR; 5/8 survival;
No infusional toxicity
Fang et al., 2007 [31] Steroid refractory,
acute GVHD
6 39 (22-49) Grade III: 2
Grade IV:4
1 M/kg adipose MSC;
1 dose (range: 1-2); mismatched/haplo MSC
5/6 CR, 4/6 survival;
No infusional toxicity
Le Blanc et al., 2008 [27] Steroid refractory,
acute GVHD
55 22 (.5-64) Grade II: 5
Grade III: 25
Grade IV:25
1.4 M/kg (range: 0.4-9);
1 dose (range: 1-5); mismatched/sib/haplo MSC
71% initial response (55% CR, 16% PR); 2-year
survival benefit for CR, 53% versus 16%;
No infusional toxicity
Von Bonin et al., 2009 [29] Steroid refractory,
acute GVHD
13 58 (21-69) Grade III: 2
Grade IV:11
0.9 M/kg (range: 0.6-1.1);
2 doses; mismatched MSC expanded in platelet
lysate-containing medium
2/13 CR, 5/13 mixed response;
4/13 alive at median 257 days;
No infusional toxicity
Kurtzburg et al., 2010 [28] Steroid refractory,
acute GVHD
59 8 Grade II: 6
Grade III: 20
Grade IV: 33
2 M/kg; 8 biweekly x4 weeks, followed by 4
infusions weekly x4 if PR; mismatched MSC
64% ORR at day 28;
76% versus 9% survival at day 100;
No infusional toxicity
Martin et al., 2010 [34] Steroid refractory,
acute GVHD
244 44 MSC; 40 control MSC vs control
II: 38 versus 23
III: 88 versus 50
IV: 47 versus 14
2 M/kg; 8 biweekly x4 weeks, followed by 4 infusions
weekly x4 if PR; mismatched MSC
No diff in durable CR b/w MSC and control; liver, GI GVHD
significantly better response 81% versus 68%, P 5 .035
Muller et al., 2008 [30] Acute/chronic GVHD 5 14 (4-17) 2 acute
3 chronic
0.4-3 M/kg
1 dose (range: 1-3); haplo MSC
2/2 acute GVHD did not progress
1/3 chronic GVHD improvement;
No infusional toxicity
GVHD indicates graft-versus-host disease; MSC, mesenchymal stromal cells; GI, gastrointestinal; CR, complete response; PR, partial response; ORR, overall response rate; M, million.
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